Publications

At PamGene we have developed a robust and unique microarray technology for multiplex kinase activity profiling. Our technology reveals the bigger picture of cellular signaling and provides mechanistic insights needed to fully understand diseases and cell alterations. On this page you will find a selection of scientific publications where PamGene’s technology has been applied.

Publications

At PamGene we have developed a robust and unique microarray technology for multiplex kinase activity profiling. On this page you will find a selection of scientific publications where PamGene’s technology has been applied.

Target interaction
Biochemical characterization
Compound-based patient stratification
Diseases model characterization
Pathway elucidation

Download our flyer with select recent publications highlighting PamGene’s kinome profiling Applications

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Hurkmans DP, Verdegaal EME, Hogan SA et al.

Journal for ImmunoTherapy of Cancer, 8:e00160 (2020).

Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC.

Hurkmans, D. et al. P2.04-06

J. Thorac. Oncol. 14, S709 (2019).

Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.

Hurkmans, D. et al.

J. Clin. Oncol. 36, 9579 (2018).

Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.

Parada, C. A. et al.

Clin. Cancer Res. clincanres.0641.2018 (2020)

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Schwill, M. et al.

Sci. Signal. 12, (2019).

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Ter Elst, A. et al.

Leuk. Lymphoma 52, 122–130 (2011).

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada, T. et al.

Oncotarget 9, 34229–34239 (2018).

Profiling activity of cellular kinases in migrating T-cells.

Chirumamilla, C. S. et al.

Methods Mol. Biol. 1930, 99–113 (2019).

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Noé, G. et al.

Cancers (Basel). 11, 762 (2019).

Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.

Bussmann L, Hoffer K, von Bargen CM, Droste C, Lange T, Kemmling J, Schröder-Schwarz J, Vu AT, Akingunsade L, Nollau P, Rangarajan S, de Wijn R et. al.
Int J Cancer. 2021 Apr 22.

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M.

Oncotarget. Aug 29. (2016)

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Havel JJ et al.

Nat. Rev. Cancer 19, 133–150 (2019).

Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status.

Alack, K. et al.

Sci Rep. Jan 21;10(1):888 (2020).

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A, Estevez-Ordonez D, Komarova S, Markert JM, Goidts V, Willey CD, Nakano I.

J Neurosurg. Oct 18:1-12.(2019)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma.

Tahiri, A. et al.

PLoS One 8, (2013).

Multiparametric Assessment of the Effects of Tyrosine Kinase Inhibitors (TKIs) on the (Electro)physiology of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes.

de Korte T, Nacken P, Pijnenburg D, Ruijtenbeek R, Stevenhagen F, Wilbers R, den Hartogh S, Groten J, Braam S and Vlaming M

Journal of Pharmacological and Toxicological Methods. 88. 236-237. 10.1016. (2017)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ.

Am J Cancer Res. Apr 1;7(4):816-830. eCollection 2017.

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu SH, Shukla R, Tomar T, Naji F, McCullumsmith RE.

Int J Mol Sci. Nov 21;21(22):8823 (2020)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmuller P, Pullamsetti SS, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT.

Nat Commun. May 17;10(1):2204.(2019)

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. Mar 18;35(3):401-413. (2019)

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.

Tosi D, Pérez-Gracia E, Atis S, Vié N, Combès E, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C.

BMC Cancer. Aug 13;18(1):812. (2018)

Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis.

Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, Weiss A, Wilhelm J, Zhang JS, Kwapiszewska G, Herold S, Schermuly RT, Mari B, Li X, Seeger W, Günther A, Bellusci S, El Agha E.

Nat Commun. Jul 5;10(1):2987. (2019)

Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion.

Blythe NM, Muraki K, Ludlow MJ, Stylianidis V, Gilbert HTJ, Evans EL, Cuthbertson K, Foster R, Swift J, Li J, Drinkhill MJ, van Nieuwenhoven FA, Porter KE, Beech DJ, Turner NA.

J Biol Chem. Oct 4. pii: jbc.RA119.009167. doi: 10.1074/jbc.RA119.009167. EPub. (2019)

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. (2019)

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.

PLoS One. (2011) Apr 18;6(4):e18522.

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase.

A. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R.

Anal Biochem. (2009) Apr 15;387 (2): 150-61.

Lithium effects on serine-threonine kinases activity: high throughput Kinomic Profiling of lymphoblastoid cell lines from excellent-responders and non-responders bipolar patients.

Moreira J, Noe G, Rangarajan S, Courtin C, Etain B, Geoffroy PA, Laplanche JL, Vidal M, Bellivier F and Marie-Claire C

The World Journal of Biological Psychiatry (2018)

Identification of Novel Substrates for cGMP Dependent Protein Kinase (PKG) through Kinase Activity Profiling to Understand Its Putative Role in Inherited Retinal Degeneration.

Roy A, Groten J, Marigo V, Tomar T, Hilhorst R.

Int J Mol Sci. Jan 25;22(3):1180 (2021)

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.

Wang J, Pollard K, Allen AN, Tomar T, Pijnenburg D, Yao Z, Rodriguez FJ, Pratilas CA

Cancer Res. Dec 1;80(23):5367-5379 (2020)

Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.

Gopinathan, U. et al.

PLoS One 13, 1–23 (2018).

Neuronal impact of patient-specific aberrant NRXN1α splicing.

Flaherty E, Zhu S, Barretto N, Cheng E, Deans PJM, Fernando MB, Schrode N, Francoeur N, Antoine A, Alganem K, Halpern M, Deikus G, Shah H, Fitzgerald M, Ladran I, Gochman P, Rapoport J, Tsankova NM, McCullumsmith R, Hoffman GE, Sebra R, Fang G, Brennand KJ.

Nat Genet. Dec;51(12):1679-1690. (2019).

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A, Estevez-Ordonez D, Komarova S, Markert JM, Goidts V, Willey CD, Nakano I.

J Neurosurg. Oct 18:1-12. (2019)

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Schwill M, Tamaskovic R, Gajadhar AS, Kast F, White FM, Plückthun A.

Sci Signal. Jan 22;12(565) (2019)

Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.

Tabbò F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, Nottegar A, Costardi L, de Wijn R, Ruijtenbeek R et. al.

Eur J Cancer. Feb;144:17-30 (2021)

STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling.

Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, Bohnenberger H, Jung K, Schroeder T, Serve H, Oellerich T, Hennighausen L, Rieger MA.

Nat Commun. Nov 25;6:8928. (2015)

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada T, Hilhorst R, Rangarajan S, Yoshida M, Tanabe Y, Tamura K, Kinoshita T, Shimoyama T, van Beuningen R, Ruijtenbeek R, Tsuda H, Koizumi F.

Oncotarget. Sep 28;9(76):34229-34239. (2018)

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.

Chocry M, Leloup L, Kovacic H.

Oncotarget. 2017 Oct 10;8(61):103710-103730.

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.

Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill PS, Salgia R.

Sci Rep. 5:10641. doi: 10.1038/srep10641. (2015)

Publications

Publications

At PamGene we have developed a robust and unique microarray technology for multiplex kinase activity profiling. On this page you will find a selection of scientific publications where PamGene’s technology has been applied.

Overview

Diagnostics

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC.

Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.

Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Profiling activity of cellular kinases in migrating T-cells.

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Biomarker discovery

Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.

Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status.

Kinase Inhibitor Discovery

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Kinase Inhibitor Optimization

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma.

Multiparametric Assessment of the Effects of Tyrosine Kinase Inhibitors (TKIs) on the (Electro)physiology of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cardiomyocytes.

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Target discovery

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.

Target interaction

Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis.

Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Biochemical characterization

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase.

Compound-based patient stratification

Lithium effects on serine-threonine kinases activity: high throughput Kinomic Profiling of lymphoblastoid cell lines from excellent-responders and non-responders bipolar patients.

Diseases Model characterization

Identification of Novel Substrates for cGMP Dependent Protein Kinase (PKG) through Kinase Activity Profiling to Understand Its Putative Role in Inherited Retinal Degeneration.

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.

Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis.

Neuronal impact of patient-specific aberrant NRXN1α splicing.

Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Pathway elucidation

Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.

STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling.

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.